On June 13, 2023, the second "West Beijing Development Forum" themed "Transforming and Nurturing New Opportunities: focus on West Beijing" was held in Shijingshan District, Beijing, at the Shougang Park. Attendees of the forum were guests from the government, corporate organizations, and authoritative media, who participated in discussions and dialogues, jointly discussing the high-quality transformation of West Beijing. The forum showcased the achievements of the region's industrial transformation in recent years and it also included a series of strategic collaborations and project signings. Over 60 enterprises, including Baheal Pharmaceutical Group and its nurtured high-end medical equipment enterprise, Huake Pioneer, signed various agreements with the "two districts and two enterprises" (Shijingshan District and Mentougou District, Shougang Group and Jingneng Power Co., Ltd) for strategic cooperation, company settlement, and project landing.

On June 11, 2023, Baheal Medical and RabPharma have embarked on a strategic collaboration focused on the commercialization of RAB001 injection (known as "RAB001"), a first-in-class innovative drug for osteonecrosis, within mainland China.

Baheal Pharma Group partnered with Peking Union Medical College Education Foundation to establish a ten-year donation project, totaling 5 million yuan, to support talent cultivation, scientific research innovation, and practice at the Institute of Systems Medicine, Chinese Academy of Medical Sciences.

On March 3rd, 2023, Baheal Pharma Group signed a strategic cooperation agreement with the Changping District government to accelerate the construction of the innovative in vitro diagnostic reagent research and development and production platform under Baheal Pharma Group.

On February 26th, 2023, Baheal Medical announced that it had recently signed a strategic cooperation agreement with Novartis China. The two parties will engage in an in-depth cooperation related to the commercial operation of Novartis' targeted therapy drug Votrient® (Pazopanib Tablets) for the first-line treatment of advanced renal cell carcinoma in the Chinese market.